<p>Rani Therapeutics Holdings, Inc.（NASDAQ:RANI - 獲取免費報告）的股票在週五的午盤交易中上漲了 1.3%。該股最高交易價格為 1.6650 美元，最後交易價格為 1.59 美元。在交易過程中，約有 2,328,448 股成交，較平均每日成交量 3,241,141 股下降了 28%。該股此前收盤價為 1.57 美元。</p>
<p>獲取 <strong>Rani Therapeutics</strong> 的提醒：</p>
<h2>華爾街分析師預測增長</h2>
<p>多家研究公司對 RANI 進行了評論。Maxim Group 將 Rani Therapeutics 的目標價格從 5.00 美元上調至 10.00 美元，並在 10 月 20 日的研究報告中給予該股 “買入” 評級。Weiss Ratings 在週二的研究報告中重申了對 Rani Therapeutics 股票的 “賣出（d-）” 評級。HC Wainwright 在 10 月 21 日的研究報告中重新發布了 “買入” 評級，並對 Rani Therapeutics 股票設定了 11.00 美元的價格目標。最後，Wall Street Zen 在 8 月 16 日的研究報告中將 Rani Therapeutics 的股票評級從 “賣出” 上調至 “持有”。四位研究分析師給予該股 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，平均價格目標為 8.50 美元。</p>
<p><strong>獲取我們關於 Rani Therapeutics 的最新報告</strong></p>
<h2>Rani Therapeutics 股票表現</h2>
<p>該公司的市值為 1.932 億美金，市盈率為-2.01，貝塔值為 0.40。該股的 50 日簡單移動平均為 1.49 美元，200 日簡單移動平均為 0.87 美元。</p>
<p>Rani Therapeutics（NASDAQ:RANI - 獲取免費報告）最近於 11 月 6 日發佈了季度財報。該公司報告每股收益為（0.12 美元），低於分析師的共識預期（0.09 美元）3 美分。平均而言，股票分析師預計 Rani Therapeutics Holdings, Inc.在本年度將發佈-1.01 的每股收益。</p>
<h2>內部人士下注</h2>
<p>在其他新聞中，主要股東 South Cone Investments Limited 於 10 月 21 日出售了 400 萬股該公司的股票。該股票以平均價格 2.77 美元出售，總交易額為 11,080,000.00 美元。出售後，內部人士在公司中持有 2,379,194 股，價值 6,590,367.38 美元。此交易代表其持股比例減少了 62.70%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。此外，董事 Mir A. Imran 於 10 月 23 日的交易中購買了 2,083,334 股 Rani Therapeutics 股票。這些股票以每股 0.60 美元的平均價格收購，總交易額為 1,250,000.40 美元。交易完成後，該董事直接持有 2,083,334 股公司股票，價值 1,250,000.40 美元。此交易代表其持股比例的∞增長。該購買的 SEC 文件提供了更多信息。公司內部人士持有公司 45.08% 的股票。</p>
<h2>機構投資者對 Rani Therapeutics 的看法</h2>
<p>幾家機構投資者和對沖基金最近增加或減少了對該公司的投資。King Luther Capital Management Corp 在第一季度將其在 Rani Therapeutics 的持股增加了 75.8%。King Luther Capital Management Corp 現在擁有 58,000 股該公司的股票，價值 73,000 美元，此前在該期間內又購買了 25,000 股。Janney Montgomery Scott LLC 在第二季度將其在 Rani Therapeutics 的持股增加了 102.9%。Janney Montgomery Scott LLC 現在擁有 55,200 股該公司的股票，價值 28,000 美元，此前在該期間內又購買了 28,000 股。Well Done LLC 在第二季度獲得了 Rani Therapeutics 的新頭寸，價值約 27,000 美元。CWA Asset Management Group LLC 在第三季度將其在 Rani Therapeutics 的持股增加了 80.0%。CWA Asset Management Group LLC 現在擁有 150,000 股該公司的股票，價值 75,000 美元，此前在該期間內又購買了 66,667 股。最後，Kestra Private Wealth Services LLC 在第三季度將其在 Rani Therapeutics 的持股增加了 44.8%。Kestra Private Wealth Services LLC 現在擁有 226,142 股該公司的股票，價值 113,000 美元，此前在該期間內又購買了 70,002 股。目前，30.19% 的股票由機構投資者和對沖基金持有。</p>
<h2>Rani Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Rani Therapeutics Holdings, Inc.是一家臨牀階段的生物治療公司，開發口服給藥的生物製劑，服務於美國的患者、醫生和醫療系統。該公司開發了 RaniPill 膠囊，這是一種藥物無關的口服給藥平台，用於傳遞多種藥物成分，包括寡核苷酸、肽、蛋白質和抗體。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票比 Rani Therapeutics 更好</li>
<li>哪裏可以找到財報電話會議記錄</li>
<li>Rocket Lab 的大反彈？分析師建議此次下跌是個機會</li>
<li>高股息 REIT：它們是理想的多元化方式嗎？</li>
<li>Meta 的 AI 時刻？新的 SAM 3 模型讓華爾街變得樂觀</li>
<li>恒生指數是什麼？</li>
<li>Snowflake 股票：聰明投資者正在購買的下跌</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Rani Therapeutics 嗎？</h2>
<p>在考慮 Rani Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Rani Therapeutics 並不在名單上。</p>
<p>雖然 Rani Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RANI

<p>Rani Therapeutics 的股票上漲了 1.3%，但交易量有所下降。分析師的評級不一，Maxim Group 將目標價上調至 10 美元，而 HC Wainwright 則設定為 11 美元。內部交易方面，一位主要股東出售了 400 萬股，而一位董事購買了超過 200 萬股。機構投資者已調整其持股，有些顯著增加了持股比例。該公司專注於口服生物製劑的遞送，市值為 1.932 億美元，市盈率為-2.01</p>

<p>Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) rose 1.3% during mid-day trading on Friday . The stock traded as high as $1.6650 and last traded at $1.59. Approximately 2,328,448 shares traded hands during trading, a decline of 28% from the average daily volume of 3,241,141 shares. The stock had previously closed at $1.57.</p>
<div class="lb-trans"><p>Rani Therapeutics Holdings, Inc.（NASDAQ:RANI - 獲取免費報告）的股票在週五的午盤交易中上漲了 1.3%。該股最高交易價格為 1.6650 美元，最後交易價格為 1.59 美元。在交易過程中，約有 2,328,448 股成交，較平均每日成交量 3,241,141 股下降了 28%。該股此前收盤價為 1.57 美元。</p>
</div><p>Get <strong>Rani Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rani Therapeutics</strong> 的提醒：</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of research firms have commented on RANI. Maxim Group boosted their target price on Rani Therapeutics from $5.00 to $10.00 and gave the stock a &#34;buy&#34; rating in a research report on Monday, October 20th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Rani Therapeutics in a research note on Tuesday. HC Wainwright reissued a &#34;buy&#34; rating and issued a $11.00 price objective on shares of Rani Therapeutics in a research note on Tuesday, October 21st. Finally, Wall Street Zen upgraded shares of Rani Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, August 16th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $8.50.</p>
<div class="lb-trans"><p>多家研究公司對 RANI 進行了評論。Maxim Group 將 Rani Therapeutics 的目標價格從 5.00 美元上調至 10.00 美元，並在 10 月 20 日的研究報告中給予該股 “買入” 評級。Weiss Ratings 在週二的研究報告中重申了對 Rani Therapeutics 股票的 “賣出（d-）” 評級。HC Wainwright 在 10 月 21 日的研究報告中重新發布了 “買入” 評級，並對 Rani Therapeutics 股票設定了 11.00 美元的價格目標。最後，Wall Street Zen 在 8 月 16 日的研究報告中將 Rani Therapeutics 的股票評級從 “賣出” 上調至 “持有”。四位研究分析師給予該股 “買入” 評級，一位給予 “賣出” 評級。根據 MarketBeat 的數據，該公司的共識評級為 “適度買入”，平均價格目標為 8.50 美元。</p>
</div><p><strong>Get Our Latest Report on Rani Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Rani Therapeutics 的最新報告</strong></p>
</div><h2>Rani Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Rani Therapeutics 股票表現</h2>
</div><p>The company has a market capitalization of $193.20 million, a PE ratio of -2.01 and a beta of 0.40. The stock's fifty day simple moving average is $1.49 and its 200-day simple moving average is $0.87.</p>
<div class="lb-trans"><p>該公司的市值為 1.932 億美金，市盈率為-2.01，貝塔值為 0.40。該股的 50 日簡單移動平均為 1.49 美元，200 日簡單移動平均為 0.87 美元。</p>
</div><p>Rani Therapeutics (NASDAQ:RANI - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.03). On average, equities analysts anticipate that Rani Therapeutics Holdings, Inc. will post -1.01 EPS for the current year.</p>
<div class="lb-trans"><p>Rani Therapeutics（NASDAQ:RANI - 獲取免費報告）最近於 11 月 6 日發佈了季度財報。該公司報告每股收益為（0.12 美元），低於分析師的共識預期（0.09 美元）3 美分。平均而言，股票分析師預計 Rani Therapeutics Holdings, Inc.在本年度將發佈-1.01 的每股收益。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>內部人士下注</h2>
</div><p>In other news, major shareholder South Cone Investments Limited sold 4,000,000 shares of the firm's stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $2.77, for a total transaction of $11,080,000.00. Following the sale, the insider owned 2,379,194 shares in the company, valued at $6,590,367.38. This trade represents a 62.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this link. Also, Director Mir A. Imran bought 2,083,334 shares of Rani Therapeutics stock in a transaction that occurred on Thursday, October 23rd. The shares were acquired at an average price of $0.60 per share, for a total transaction of $1,250,000.40. Following the completion of the transaction, the director directly owned 2,083,334 shares of the company's stock, valued at $1,250,000.40. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 45.08% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，主要股東 South Cone Investments Limited 於 10 月 21 日出售了 400 萬股該公司的股票。該股票以平均價格 2.77 美元出售，總交易額為 11,080,000.00 美元。出售後，內部人士在公司中持有 2,379,194 股，價值 6,590,367.38 美元。此交易代表其持股比例減少了 62.70%。該交易已在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接獲取。此外，董事 Mir A. Imran 於 10 月 23 日的交易中購買了 2,083,334 股 Rani Therapeutics 股票。這些股票以每股 0.60 美元的平均價格收購，總交易額為 1,250,000.40 美元。交易完成後，該董事直接持有 2,083,334 股公司股票，價值 1,250,000.40 美元。此交易代表其持股比例的∞增長。該購買的 SEC 文件提供了更多信息。公司內部人士持有公司 45.08% 的股票。</p>
</div><h2>Institutional Investors Weigh In On Rani Therapeutics</h2>
<div class="lb-trans"><h2>機構投資者對 Rani Therapeutics 的看法</h2>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. King Luther Capital Management Corp raised its holdings in shares of Rani Therapeutics by 75.8% in the 1st quarter. King Luther Capital Management Corp now owns 58,000 shares of the company's stock worth $73,000 after purchasing an additional 25,000 shares during the period. Janney Montgomery Scott LLC raised its holdings in Rani Therapeutics by 102.9% in the second quarter. Janney Montgomery Scott LLC now owns 55,200 shares of the company's stock valued at $28,000 after buying an additional 28,000 shares during the period. Well Done LLC acquired a new position in Rani Therapeutics during the second quarter valued at approximately $27,000. CWA Asset Management Group LLC grew its stake in Rani Therapeutics by 80.0% during the third quarter. CWA Asset Management Group LLC now owns 150,000 shares of the company's stock worth $75,000 after buying an additional 66,667 shares during the period. Finally, Kestra Private Wealth Services LLC grew its stake in Rani Therapeutics by 44.8% during the third quarter. Kestra Private Wealth Services LLC now owns 226,142 shares of the company's stock worth $113,000 after buying an additional 70,002 shares during the period. 30.19% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>幾家機構投資者和對沖基金最近增加或減少了對該公司的投資。King Luther Capital Management Corp 在第一季度將其在 Rani Therapeutics 的持股增加了 75.8%。King Luther Capital Management Corp 現在擁有 58,000 股該公司的股票，價值 73,000 美元，此前在該期間內又購買了 25,000 股。Janney Montgomery Scott LLC 在第二季度將其在 Rani Therapeutics 的持股增加了 102.9%。Janney Montgomery Scott LLC 現在擁有 55,200 股該公司的股票，價值 28,000 美元，此前在該期間內又購買了 28,000 股。Well Done LLC 在第二季度獲得了 Rani Therapeutics 的新頭寸，價值約 27,000 美元。CWA Asset Management Group LLC 在第三季度將其在 Rani Therapeutics 的持股增加了 80.0%。CWA Asset Management Group LLC 現在擁有 150,000 股該公司的股票，價值 75,000 美元，此前在該期間內又購買了 66,667 股。最後，Kestra Private Wealth Services LLC 在第三季度將其在 Rani Therapeutics 的持股增加了 44.8%。Kestra Private Wealth Services LLC 現在擁有 226,142 股該公司的股票，價值 113,000 美元，此前在該期間內又購買了 70,002 股。目前，30.19% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Rani Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Rani Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.</p>
<div class="lb-trans"><p>Rani Therapeutics Holdings, Inc.是一家臨牀階段的生物治療公司，開發口服給藥的生物製劑，服務於美國的患者、醫生和醫療系統。該公司開發了 RaniPill 膠囊，這是一種藥物無關的口服給藥平台，用於傳遞多種藥物成分，包括寡核苷酸、肽、蛋白質和抗體。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Rani Therapeutics</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li>
<li>What is the Hang Seng index?</li>
<li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Rani Therapeutics 更好</li>
<li>哪裏可以找到財報電話會議記錄</li>
<li>Rocket Lab 的大反彈？分析師建議此次下跌是個機會</li>
<li>高股息 REIT：它們是理想的多元化方式嗎？</li>
<li>Meta 的 AI 時刻？新的 SAM 3 模型讓華爾街變得樂觀</li>
<li>恒生指數是什麼？</li>
<li>Snowflake 股票：聰明投資者正在購買的下跌</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rani Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Rani Therapeutics 嗎？</h2>
</div><p>Before you consider Rani Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Rani Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Rani Therapeutics 並不在名單上。</p>
</div><p>While Rani Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rani Therapeutics 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Rani Therapeutics（NASDAQ:RANI）股價上漲 1.3% - 以下是原因